US Patent

US10851091 — Benzoxazepin oxazolidinone compounds and methods of use

Composition of Matter · Assigned to Genentech Inc · Expires 2036-07-01 · 10y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity, as well as pharmaceutical compositions and methods of using these compounds.

USPTO Abstract

Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.

Drugs covered by this patent

Patent Metadata

Patent number
US10851091
Jurisdiction
US
Classification
Composition of Matter
Expires
2036-07-01
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Genentech Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.